证券之星消息，12月25日生物制品板块较上一交易日上涨0.18%，金迪克领涨。当日上证指数报收于 3959.62，上涨0.47%。深证成指报收于13531.41，上涨0.33%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688670 | 金克 | 22.45 | 4.66% | 6.68万 | 1.48亿 | | 688443 | 智翔金泰 | 27.07 | 3.08% | 3.78万 | 1.01亿 | | 000518 | *ST四环 | 2.46 | 2.93% | 10.92万 | 2642.85万 | | 000534 | 万泽股份 | 24.15 | 2.33% | 20.35万 | 4.88亿 | | 688520 | 神州细胞 | 44.55 | 1.71% | 2.72万 | 261T | | 301080 | 百普賽斯 | 55.23 | 1.56% | 1.40万 | 7720.60万 | | 002773 | 康弘药业 | 31.17 ...

12月25日，智翔金泰盘中上涨2.02%，截至13:54，报26.79元/股，成交6233.43万元，换手率2.03%，总 市值98.23亿元。 智翔金泰所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：生物医药、创新 药、小盘、融资融券、基金重仓等。 截至9月30日，智翔金泰股东户数1.26万，较上期增加7.75%；人均流通股9231股，较上期减少7.19%。 2025年1月-9月，智翔金泰实现营业收入2.08亿元，同比增长1562.05%；归母净利润-3.33亿元，同比增 长39.12%。 机构持仓方面，截止2025年9月30日，智翔金泰十大流通股东中，工银前沿医疗股票A（001717）位居 第一大流通股东，持股408.65万股，相比上期减少257.35万股。富国优化增强债券C（100037）位居第 四大流通股东，持股300.00万股，为新进股东。鹏华医药科技股票A（001230）位居第六大流通股东， 持股283.29万股，相比上期减少31.48万股。香港中央结算有限公司位居第七大流通股东，持股196.00万 股，为新进股东。东方红医疗升级股票发起A（015052）位居第八大流通股东，持 ...

证券日报网讯12月23日，智翔金泰发布公告称，因徐伟东工作变动，信永中和不再指派其担任公司2025 年度审计项目签字注册会计师，现委派罗军先生、张杭女士为签字注册会计师，继续完成公司2025年度 财务报告审计的相关工作。本次变更后，为公司提供2025年度审计服务的项目合伙人、签字注册会计师 分别为罗军先生、张杭女士。 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2025-052 重庆智翔金泰生物制药股份有限公司 关于变更签字注册会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重庆智翔金泰生物制药股份有限公司（以下简称"公司"或"本公司"）于 2025 年 4 月 25 日召开第二届董事会第二次会议、第二届监事会第二次会议，于 2025 年 6 月 18 日召开 2024 年年度股东大会，审议通过了《关于续聘公司 2025 年度审计机构的议案》，同意续聘信永中和会计师事务所（特殊普通合伙）（以下 简称"信永中和"）为本公司及下属子公司 2025 年度的审计机构，聘期 1 年。具 体内容详见公司于 2025 年 4 月 26 日在上海证券交易所网站（www.sse.com.cn） 披露的《关于续聘公司 2025 年度审计机构的公告》（公告编号：2025-018）。 近日，公司收到信永中和出具的《关于变更重庆智翔金泰生物制药股份有限 公司 2025 年度签字注册会计师的告知函》，现将相关变更情况公告如下： 一、本次签字 ...

智翔金泰已连亏4年3季。2021年至2024年，智翔金泰归属于上市公司股东的净利润分别为-3.22亿 元、-5.76亿元、-8.01亿元、-7.97亿元；归属于上市公司股东的扣非净利润分别为-3.34亿元、-6.45亿 元、-8.13亿元、-8.04亿元。 2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股 东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产 生的现金流量净额为-2.61亿元。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为 329,140.14万元。智翔金泰实际募资净额比原拟募集资金金额少68,859.86万元。智翔金泰于2023年6 月15日披露的招股说明书显示，该公司拟募集资金398,000.00万元，用于抗体产业化基地项目一期改 扩建、抗体产业化基地项目二期、抗体药物研发项目、补充流动资金。 智翔金泰首次公开发行股票的发行费用合计18,143.70万元（不含税），其中，保荐承销费 16,495.98万元。 中国经济网北京12月15日讯 智翔 ...

Core Viewpoint - In 2025, the Chinese A-share market is showing a steady upward trend supported by favorable policies, with the China Securities Regulatory Commission urging listed companies to increase dividends, buybacks, and shareholdings to solidify their value foundation [1] Group 1: Executive Buybacks - Since 2025, 27 companies in the A-share market have seen significant executive buybacks, particularly in high-growth sectors like healthcare, new energy, and semiconductors [2] - For instance, Kelly Tai's executives increased their holdings by 2.3 million shares, a 14% increase, benefiting from the growing orthopedic medical demand due to an aging population [2] - DeYe shares' executives bought 120,000 shares, while Tuojing Technology's executives increased their holdings by 210,000 shares, a 12% rise, aligning with national policies on technological self-reliance [2] Group 2: Policy Support - Multiple significant policies in 2025 have led to a surge in positive announcements from listed companies, with 14 companies benefiting from adjustments in the national medical insurance catalog and the encouragement of private investment [3][5] - The national medical insurance catalog added 114 new drugs, including 50 innovative drugs, significantly enhancing the market accessibility and sales scale for companies like Junshi Biosciences and Hengrui Medicine [5] - The release of 13 opinions by the State Council encourages private capital participation in key sectors like railways and nuclear power, with companies like China Railway Construction benefiting from substantial project contracts [5] Group 3: Performance Support - Many of the 14 companies have solid operational performance, signing significant contracts or achieving key technological breakthroughs that underpin their investment value [6][7] - For example, JinkoSolar's TigerNeo 3.0 components achieved a production efficiency of 24.8% and secured global orders worth 15 GW, showcasing its competitive edge in the solar market [7] - Research and development investments in A-shares reached 745.69 billion yuan in the first half of 2025, with sectors like electronics and biomedicine leading the way, indicating a strong foundation for future growth [7] Group 4: Investment Opportunities - Investors should focus on companies with executive buybacks in high-growth sectors, those benefiting from policy adjustments, and firms with significant contracts or R&D breakthroughs [8][9][10] - The combination of internal confidence from executives and favorable industry trends creates a strong investment rationale [8] - Companies directly benefiting from long-term policy releases, such as those in the medical and infrastructure sectors, present stable investment opportunities [9]

Core Points - The company announced that its wholly-owned subsidiary, Xinjunquan Microelectronics, has completed the registration of an industrial fund, significantly increasing its total subscribed capital from RMB 150.1 million to RMB 250.1 million [1][3] - The introduction of a new limited partner, Huafu Growth Investment Co., Ltd., which has committed RMB 100 million, diversifies the funding structure of the partnership, enhancing flexibility in funding sources and resource collaboration [3] - The fund will be managed by Shanghai Daohua Long-term Investment Management Co., Ltd., which will oversee daily operations and risk control, ensuring compliance with legal and regulatory requirements [3] Summary by Sections Fund Registration and Capital Increase - The industrial fund has received its business license from the Zhangjiagang Data Bureau and has been registered with the Asset Management Association of China, obtaining the private investment fund registration certificate [1] - The total subscribed capital of the partnership has increased significantly, with the company's contribution remaining at RMB 66 million, resulting in a change in its ownership percentage from 99.93% to 59.98% [1][3] New Limited Partner and Structural Changes - The new limited partner, Huafu Growth Investment Co., Ltd., contributes RMB 100 million, which corresponds to a 39.98% stake in the partnership [3] - This change shifts the partnership from a predominantly company-controlled structure to a more diversified model involving external institutions, enhancing the fund's investment capacity and project support capabilities [3] Management and Operational Impact - The fund's daily management and risk control will continue to be handled by Shanghai Daohua Long-term Investment Management Co., Ltd., ensuring that the operational framework remains intact [3] - The company asserts that the addition of new partners and the capital increase will not adversely affect its financial status or operational activities, nor will it harm the legal rights of the company and its shareholders [3]

智翔金泰已连亏4年3季。2021年至2024年，智翔金泰归属于上市公司股东的净利润分别为-3.22亿 元、-5.76亿元、-8.01亿元、-7.97亿元；归属于上市公司股东的扣非净利润分别为-3.34亿元、-6.45亿 元、-8.13亿元、-8.04亿元。 2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股 东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产 生的现金流量净额为-2.61亿元。 (责任编辑：徐自立) 中国经济网北京12月8日讯 智翔金泰(688443.SH)今日收报27.67元，跌幅1.00%。该股目前处于破 发状态。 智翔金泰于2023年6月20日在上交所科创板上市，公开发行新股9,168.0000万股，发行价格为 37.88元/股，保荐机构（主承销商）为海通证券股份有限公司（现名"国泰海通证券股份有限公司"）， 保荐代表人为王永杰、刘丹。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为 329,140.14万元。智翔金泰实际募资净额比原拟募集资 ...

Group 1 - Century Huatong plans to change the use of 1.28 million repurchased shares from equity incentive plans to cancellation, reducing total share capital from 7.428 billion to 7.427 billion shares [2] - Wuliangye adjusts its 2025 investment plan, increasing the number of projects from 19 to 22 and changing the investment amount from 2.586 billion to 2.207 billion yuan [3] - Qingyue Technology is under investigation for suspected financial data fraud, with the possibility of forced delisting if found guilty [4] Group 2 - Kang Enbei's chairman and legal representative resigns due to work adjustments, along with another board member [5] - Tianshan Co. expects a tax payment of approximately 61.86 million yuan to impact its 2025 net profit [6] - Muyuan Foods reports a 20.43% year-on-year decline in November sales revenue from live pigs, totaling 9.39 billion yuan [7] Group 3 - GAC Group's November automobile sales decreased by 9.72% year-on-year, with total sales of 1.797 million vehicles [8] - Western Pastoral's fresh milk production in November increased by 6.3% month-on-month but decreased by 6.47% year-on-year [9] - Gemdale Group's November contracted area fell by 58.50% year-on-year, with a total contracted amount of 1.52 billion yuan [10] Group 4 - Zhenghong Technology reports November sales revenue of 4.5196 million yuan from live pigs, with a year-on-year decline of 21.83% [11] - Wens Foodstuff's November chicken sales reached 118 million birds, generating 3.324 billion yuan in revenue [12] - Meilixin's controlling shareholder plans to increase holdings by no less than 50 million yuan [13] Group 5 - Hongcheng Environment's subsidiary wins an 853 million yuan sewage treatment project [14] - Dongzhu Ecology wins a 397 million yuan environmental project [15] - Xindian Software secures a 54 million yuan project for digital community construction [16] Group 6 - China Chemical announces that its nylon new material project has reached full production [17] - Jiaojian Co. is in discussions regarding overdue payments related to financial products, clarifying that it bears no responsibility for these products [18] - Micron Biotech's product is included in the 2025 National Medical Insurance Directory [19] Group 7 - Yitian Intelligent plans to sell 600 smart computing machines for a total of 1.56 billion yuan [20] - First Venture's subsidiary receives an administrative penalty notice from Jiangsu Securities Regulatory Bureau [21] - China Insurance's vice president is under investigation for serious violations [22] Group 8 - Zhixiang Jintai's monoclonal antibody injection is included in the 2025 National Medical Insurance Directory [23] - Haichuang Pharmaceutical's drug is also included in the National Medical Insurance Directory [24] - Yuanli Co. plans to acquire 49% of Clarimex for 25.56 million USD [25] Group 9 - Betta Pharmaceuticals' products are included in the National Medical Insurance Directory [26] - Tianci Materials' controlling shareholder commits to not reducing holdings for six months [27] - Guanglian Aviation's actual controller has had a detention measure lifted [28] Group 10 - Annie Co. announces a share transfer agreement that will make Shengshi Tianan the controlling shareholder [29] - Double Star New Materials notes uncertainty regarding the sustainability of long-term price increases [30] - ST Tianrui terminates plans for a change in control and resumes trading [31] Group 11 - Guao Technology is planning a change in control, leading to a temporary suspension of its stock [32] - Guangqi Technology's subsidiary signs contracts worth 696 million yuan for the production of metamaterials [33] - Shuoshi Biotech's monkeypox virus detection kit is included in the WHO emergency use list [34]

药品分类：白介素抑制剂 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据国家医保局、人力资源社会保障部《关于印发〈国家基本医疗保险、生育保险和工伤保险药品目 录〉以及〈商业健康保险创新药品目录〉(2025年)的通知》，重庆智翔金泰生物制药股份有限公司（以 下简称"公司"）自主研发的赛立奇单抗注射液（金立希）成功纳入《国家基本医疗保险、生育保险和工 伤保险药品目录》（以下简称"国家医保目录"）。新版国家医保目录将自2026年1月1日起正式实施。现 将相关信息公告如下： 一、产品纳入国家医保目录的情况 药品名称：赛立奇单抗注射液 商品名：金立希 注册类别：治疗用生物制品Ⅰ类 本次赛立奇单抗注射液被纳入国家医保目录，体现了国家医疗保障局对临床价值高、患者获益大的创新 药品的支持和认可，也将有利于进一步推动赛立奇单抗注射液的市场推广及未来销售，对公司长期经营 业绩产生积极影响。 新版国家医保目录将于2026年1月1日起正式执行，医保支付标准、医保报销细则等相关信息，需以国家 医保局等相关政府部门公示信息为准。此外，公司产品销售将受 ...